Drug Profile


Alternative Names: ARQ-197

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ArQule
  • Developer ArQule; Daiichi Sankyo Company; Istituto Clinico Humanitas; Istituto Oncologico Veneto; Kyowa Hakko Kirin; National Cancer Institute (USA); National Institutes of Health (USA); SCRI Development Innovations
  • Class Antineoplastics; Pyrrolidinones; Quinolines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Colorectal cancer; Head and neck cancer; Mesothelioma; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase I/II Solid tumours
  • Discontinued Gastric cancer; Germ cell and embryonal neoplasms; Non-small cell lung cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 09 Mar 2017 ArQule has patent protection for tivantinib in US, Japan, the EU, South Korea, Singapore, Australia, China, Mexico, New Zealand, Philippines, Russia and South Africa (ArQule's form 10-K, filed in March 2017)
  • 09 Mar 2017 ArQule has patents pending for tivantinib in USA and countries outside USA (ArQule's form 10-K, filed in March 2017)
  • 17 Feb 2017 Daiichi Sankyo and ArQule complete the phase III METIV-HCC trial in Hepatocellular carcinoma (Inoperable/Unresectable, Monotherapy, Second-line therapy or greater) in Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, New Zealand, Portugal, Spain, Sweden, Switzerland, and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top